Payment overview · 2025
General Payments
$736.46
28 reported records · 11 companies
Healthcare provider profile · identity verified
Sabah Kadhium, MD
Allopathic & Osteopathic Physicians|Family Medicine · SAN DIMAS, CA · NPI 1306836770
Verified facts
What the public records show
CMS Open Payments records show Sabah Kadhium, MD received $736.46 in general payments during 2025 across 28 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rexulti.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 724 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $197.90 | 26.9% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $85.43 | 11.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $75.70 | 10.3% | 3 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $75.14 | 10.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.70 | 10.0% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $64.12 | 8.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.10 | 6.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $41.98 | 5.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.20 | 3.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.08 | 3.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.11 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $736.46 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $197.90 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $117.68 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $101.35 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $85.43 | 3 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $75.14 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $64.12 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.29 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.20 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.20 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.20 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $22.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 138 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 137 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
137 | 25 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
724 | 75 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1163 | 202 |
| Amlodipine Besylate | Amlodipine Besylate | 805 | 136 |
| Eliquis | Apixaban | 724 | 75 |
| Gabapentin | Gabapentin | 713 | 108 |
| Losartan Potassium | Losartan Potassium | 693 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 622 | 96 |
| Famotidine | Famotidine | 604 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 577 | 115 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 574 | 89 |
| Metoprolol Tartrate | Metoprolol Tartrate | 563 | 74 |
| Carvedilol | Carvedilol | 517 | 78 |
| Donepezil Hcl | Donepezil Hcl | 451 | 62 |
| Memantine Hcl | Memantine Hcl | 446 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 446 | 87 |
| Lisinopril | Lisinopril | 429 | 79 |
| Divalproex Sodium | Divalproex Sodium | 414 | 47 |
| Omeprazole | Omeprazole | 394 | 62 |
| Metformin Hcl | Metformin Hcl | 388 | 82 |
| Furosemide | Furosemide | 356 | 63 |
| Simvastatin | Simvastatin | 343 | 48 |
| Quetiapine Fumarate | Quetiapine Fumarate | 341 | 41 |
| Potassium Chloride | Potassium Chloride | 336 | 47 |
| Levetiracetam | Levetiracetam | 332 | 47 |
| Trazodone Hcl | Trazodone Hcl | 309 | 53 |
| Alprazolam | Alprazolam | 303 | 46 |
| Xarelto | Rivaroxaban | 279 | 33 |
| Fenofibrate | Fenofibrate Nanocrystallized | 259 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 250 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 247 | 58 |
| Diclofenac Sodium | Diclofenac Sodium | 245 | 53 |
| Tramadol Hcl | Tramadol Hcl | 238 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 230 | 56 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 219 | 23 |
| Albuterol Sulfate | Albuterol Sulfate | 218 | 23 |
| Lorazepam | Lorazepam | 209 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 203 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 202 | 28 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 199 | 22 |
| Spironolactone | Spironolactone | 189 | 34 |
| Ondansetron Hcl | Ondansetron Hcl | 182 | 66 |
| Clonazepam | Clonazepam | 176 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 175 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 173 | 30 |
| Olanzapine | Olanzapine | 171 | 26 |
| Baclofen | Baclofen | 169 | 27 |
| Lactulose | Lactulose | 166 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 27 |
| Mirtazapine | Mirtazapine | 154 | 22 |
| Alendronate Sodium | Alendronate Sodium | 140 | 24 |
| Amiodarone Hcl | Amiodarone Hcl | 138 | 17 |
| Jardiance | Empagliflozin | 138 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 26 |
| Ozempic | Semaglutide | 137 | 25 |
| Midodrine Hcl | Midodrine Hcl | 134 | 19 |
| Finasteride | Finasteride | 133 | 24 |
| Ibuprofen | Ibuprofen | 131 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 129 | 24 |
| Megestrol Acetate | Megestrol Acetate | 129 | 24 |
| Temazepam | Temazepam | 127 | 19 |
| Meclizine Hcl | Meclizine Hcl | 124 | 25 |
| Glipizide | Glipizide | 119 | 23 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 119 | 34 |
| Atenolol | Atenolol | 118 | 23 |
| Azithromycin | Azithromycin | 118 | 62 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 117 | 16 |
| Clonidine Hcl | Clonidine Hcl | 117 | 37 |
| Sertraline Hcl | Sertraline Hcl | 112 | 24 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 108 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | suppressed |
| Humulin R | Insulin Regular, Human | 105 | 23 |
| Latanoprost | Latanoprost | 104 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 100 | 62 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 99 | 42 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 99 | 32 |
| Sodium Chloride | 0.9 % Sodium Chloride | 98 | 23 |
| Montelukast Sodium | Montelukast Sodium | 95 | 17 |
| Propranolol Hcl | Propranolol Hcl | 94 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 91 | 13 |
| Warfarin Sodium | Warfarin Sodium | 91 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 89 | 15 |
| Naproxen | Naproxen | 89 | 41 |
| Nystatin | Nystatin | 89 | 50 |
| Prednisone | Prednisone | 86 | 27 |
| Meloxicam | Meloxicam | 82 | 14 |
| Benazepril Hcl | Benazepril Hcl | 81 | 12 |
| Glimepiride | Glimepiride | 78 | 18 |
| Pregabalin | Pregabalin | 76 | 19 |
| Santyl | Collagenase Clostridium Hist. | 76 | 22 |
| Allopurinol | Allopurinol | 75 | 21 |
| Novolin R | Insulin Regular, Human | 75 | 13 |
| Buspirone Hcl | Buspirone Hcl | 74 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 73 | 11 |
| Sucralfate | Sucralfate | 73 | suppressed |
| Celecoxib | Celecoxib | 72 | 13 |
| Linzess | Linaclotide | 71 | 11 |
| Novolog Flexpen | Insulin Aspart | 71 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 70 | 13 |
| Austedo | Deutetrabenazine | 69 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 69 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 66 | suppressed |
| Valsartan | Valsartan | 66 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 15 |
| Januvia | Sitagliptin Phosphate | 65 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 64 | suppressed |
| Lidocaine | Lidocaine | 64 | 15 |
| Mupirocin | Mupirocin | 64 | 46 |
| Myrbetriq | Mirabegron | 62 | 11 |
| Lansoprazole | Lansoprazole | 60 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 58 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 58 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 32 |
| Sodium Chloride | Sodium Chloride 0.45 % | 55 | 11 |
| Enoxaparin Sodium | Enoxaparin Sodium | 54 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 53 | 11 |
| Digoxin | Digoxin | 53 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 53 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 53 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 53 | suppressed |
| Aripiprazole | Aripiprazole | 51 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 51 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 51 | 23 |
| Clobetasol Propionate | Clobetasol Propionate | 49 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 49 | 27 |
| Tradjenta | Linagliptin | 49 | suppressed |
| Epogen | Epoetin Alfa | 47 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 46 | suppressed |
| Cyclosporine | Cyclosporine | 42 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 42 | suppressed |
| Risperidone | Risperidone | 42 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 41 | 17 |
| Humalog | Insulin Lispro | 41 | suppressed |
| Irbesartan | Irbesartan | 41 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 40 | suppressed |
| Lacosamide | Lacosamide | 40 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 39 | 39 |
| Gemfibrozil | Gemfibrozil | 39 | suppressed |
| Haloperidol | Haloperidol | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Carbamazepine | Carbamazepine | 38 | suppressed |
| Fentanyl | Fentanyl | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Colchicine | Colchicine | 37 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 23 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 34 | suppressed |
| Permethrin | Permethrin | 34 | 29 |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Acyclovir | Acyclovir | 33 | 12 |
| Cephalexin | Cephalexin | 33 | 27 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 32 | suppressed |
| Clonidine | Clonidine | 32 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 31 | 11 |
| Methotrexate | Methotrexate Sodium | 31 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 31 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Entacapone | Entacapone | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Rexulti | Brexpiprazole | 29 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 28 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Nystop | Nystatin | 28 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 28 | suppressed |
| Timolol Maleate | Timolol Maleate | 28 | suppressed |
| Clotrimazole | Clotrimazole | 27 | 11 |
| Diazepam | Diazepam | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 27 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 27 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 26 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 18 |
| Ziprasidone Hcl | Ziprasidone Hcl | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 14 |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Ingrezza | Valbenazine Tosylate | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 22 |
| Glucagon Emergency Kit | Glucagon | 24 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Nateglinide | Nateglinide | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 16 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Alogliptin | Alogliptin Benzoate | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Phenytoin | Phenytoin | 20 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Novolog | Insulin Aspart | 19 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 19 | 18 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Prolia | Denosumab | 18 | 11 |
| Bimatoprost | Bimatoprost | 17 | suppressed |
| Dextrose 5%-0.9% Nacl | Dextrose 5 % And 0.9 % Nacl | 17 | 13 |
| Glipizide Er | Glipizide | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Silodosin | Silodosin | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Ertapenem | Ertapenem Sodium | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Procrit | Epoetin Alfa | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Acetazolamide Er | Acetazolamide | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Np Thyroid | Thyroid,pork | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Rhopressa | Netarsudil Mesylate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Travoprost | Travoprost | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Tivicay | Dolutegravir Sodium | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Vytorin | Ezetimibe/Simvastatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $736.46 · 28 records | Teva Pharmaceuticals USA, Inc. | ABRYSVO, AUSTEDO XR, CAPVAXIVE, COMIRNATY, GARDASIL 9, JARDIANCE, KISUNLA, Kerendia, LifeVest, M-M-R II, Ozempic, PREVNAR 20, REXULTI, Rybelsus, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error